Want to see HK:2563 full AI Analyst Report?
Top Page
Beijing Biostar Pharmaceuticals Co., Ltd. Class H
(2563)
Select Model
Select Model
Rating:51Neutral
Price Target:
HK$4.50
▼(-29.25% Downside)
Action:Reiterated
Date:10/01/26
The score is held back primarily by weak financial performance—sharp revenue decline, persistent heavy losses, and ongoing cash burn—despite a low-debt balance sheet. Technicals provide some support due to a strong uptrend and positive MACD, but overbought readings increase near-term risk. Valuation remains constrained by negative earnings (negative P/E) and no dividend yield data.
Positive Factors
Very low leverage
The extremely low debt burden reduces solvency and refinancing pressure, preserving financial flexibility as the company funds pharmaceutical development and commercialization. Although low leverage does not resolve losses, it provides a more resilient capital structure than a heavily indebted model.
Negative Factors
Sharp revenue decline and volatility
The sharp 2025 contraction and history of volatile revenue make the company’s commercial trajectory difficult to rely on over the next several quarters. Unstable sales can reduce operating leverage, complicate investment planning, and make persistent losses harder to reverse.
Read all positive and negative factors
Positive Factors
Negative Factors
Very low leverage
The extremely low debt burden reduces solvency and refinancing pressure, preserving financial flexibility as the company funds pharmaceutical development and commercialization. Although low leverage does not resolve losses, it provides a more resilient capital structure than a heavily indebted model.
Read all positive factors
Beijing Biostar Pharmaceuticals Co., Ltd. Class H (2563) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.68B
Dividend YieldN/A
Average Volume (3M)35.61K
Price to Earnings (P/E)―
Beta (1Y)0.26
Revenue GrowthN/A
EPS GrowthN/A
CountryHK
Employees134
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.34
Shares Outstanding389,588,000
10 Day Avg. Volume56,680
30 Day Avg. Volume35,613
Financial Highlights & Ratios
PEG Ratio1.35
Price to Book (P/B)2.41
Price to Sales (P/S)48.10
P/FCF Ratio-10.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Beijing Biostar Pharmaceuticals Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Beijing Biostar Pharmaceuticals Co. Ltd. primarily focuses on developing innovative therapies for tumors. The company is dedicated to creating novel anti-cancer drugs, each secured by independent intellectual property rights. A prominent product i...
Beijing Biostar Pharmaceuticals Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
15
Very Negative
| Breakdown | TTM | Dec 2025 | Jun 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 64.58M | 37.12M | 77.92M | 73.75M | 37.38M | 106.74M |
| Gross Profit | 59.71M | 33.65M | 66.75M | 51.83M | 27.20M | 100.48M |
| EBITDA | -105.53M | -139.77M | -173.84M | -198.08M | -170.77M | -430.65M |
| Net Income | -124.61M | -142.54M | -155.89M | -209.90M | -182.81M | -417.79M |
Balance Sheet | ||||||
| Total Assets | 855.87M | 861.37M | 971.51M | 854.83M | 1.06B | 1.45B |
| Cash, Cash Equivalents and Short-Term Investments | 516.22M | 508.15M | 609.16M | 637.54M | 830.57M | 988.06M |
| Total Debt | 1.61M | 2.20M | 1.26M | 995.01K | 2.17M | 1.72M |
| Total Liabilities | 116.80M | 120.36M | 130.31M | 54.44M | 66.53M | 30.34M |
| Stockholders Equity | 739.07M | 741.01M | 841.20M | 800.40M | 988.49M | 1.42B |
Cash Flow | ||||||
| Free Cash Flow | -67.06M | -174.59M | -163.18M | -197.69M | -127.69M | -134.93M |
| Operating Cash Flow | -63.63M | -168.56M | -119.77M | -166.88M | -90.47M | -118.32M |
| Investing Cash Flow | -14.74M | 99.59M | 56.88M | 145.30M | -167.18M | 192.93M |
| Financing Cash Flow | -1.52M | -1.39M | 221.38M | -1.25M | 4.02M | -1.21M |
Beijing Biostar Pharmaceuticals Co., Ltd. Class H Technical Analysis
Neutral
6.36
Price Trends
3.89
Positive
3.77
Positive
3.77
Positive
Market Momentum
0.23
Negative
51.03
Neutral
81.30
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2563, the sentiment is Neutral. The current price of 6.36 is above the 20-day moving average (MA) of 4.36, above the 50-day MA of 3.89, and above the 200-day MA of 3.77, indicating a neutral trend. The MACD of 0.23 indicates Negative momentum. The RSI at 51.03 is Neutral, neither overbought nor oversold. The STOCH value of 81.30 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:2563.
Beijing Biostar Pharmaceuticals Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
85 Outperform | HK$1.36B | 4.12 | 15.91% | 11.31% | 0.20% | 24.13% | |
59 Neutral | HK$6.93B | 8.49 | 4.40% | 2.66% | 2.84% | 71.92% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | HK$1.16B | 120.10 | 3.67% | ― | 38.59% | ― | |
51 Neutral | HK$1.68B | -12.51 | -16.60% | ― | ― | ― | |
49 Neutral | HK$1.13B | -10.35 | 30.32% | ― | -8.00% | 51.26% |
* General Sector Average
HK:2563
Beijing Biostar Pharmaceuticals Co., Ltd. Class H
4.30
-3.36
-43.86%
HK:2186
Luye Pharma Group
1.77
-1.65
-48.24%
HK:8049
Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H
2.42
0.47
24.36%
HK:1228
CANbridge Pharmaceuticals Inc.
1.89
-0.56
-22.86%
HK:6086
Fangzhou Inc.
0.84
-3.04
-78.35%
HK:2566
Hangzhou Jiuyuan Gene Engineering Co Ltd Class H
5.65
-4.68
-45.31%
Beijing Biostar Pharmaceuticals Co., Ltd. Class H Corporate Events
Beijing Biostar Pharmaceuticals Doubles Revenue and Narrows Losses in First Half of 2026
Aug 26, 2026
Beijing Biostar Pharmaceuticals reported a sharp improvement in interim financial performance for the six months ended June 30, 2026, with revenue rising 147.8% year-on-year to RMB36.6 million and gross profit increasing at a similar pace. Despite...
Beijing Biostar Pharmaceuticals Sets Board Meeting to Review Interim Results and Dividend
Aug 12, 2026
Beijing Biostar Pharmaceuticals has scheduled a board meeting for 26 August 2026 to review its consolidated interim results for the six months ended 30 June 2026 and to consider their publication. The meeting will also discuss whether to recommend...
Beijing Biostar completes HK$4.00-per-share subscription, expanding equity base
Jul 16, 2026
Beijing Biostar Pharmaceuticals has completed a share subscription under its general mandate, issuing 25 million new H-shares at HK$4.00 each to a single subscriber. Following the transaction, the company’s total share capital rose from 364....
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.